Compare · ALRN vs VKTX
ALRN vs VKTX
Side-by-side comparison of Aileron Therapeutics Inc. (ALRN) and Viking Therapeutics Inc. (VKTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALRN and VKTX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- VKTX is the larger of the two at $3.99B, about 105.6x ALRN ($37.7M).
- VKTX has hit the wire 2 times in the past 4 weeks while ALRN has been quiet.
- VKTX has more recent analyst coverage (23 ratings vs 0 for ALRN).
- Company
- Aileron Therapeutics Inc.
- Viking Therapeutics Inc.
- Price
- -
- -
- Market cap
- $37.7M
- $3.99B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2015
- News (4w)
- 0
- 2
- Recent ratings
- 0
- 23
Aileron Therapeutics Inc.
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. Aileron Therapeutics, Inc. has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.
Viking Therapeutics Inc.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRÃ), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRÃ for X-linked adrenoleukodystrophy. Viking Therapeutics, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Latest ALRN
- SEC Form 8-K filed by Aileron Therapeutics Inc.
- Aileron Therapeutics Announces Rebranding to Rein Therapeutics
- President and CEO Windsor James Brian bought $898 worth of shares (400 units at $2.24) (SEC Form 4)
- SEC Form 4 filed by Director Aivado Manuel
- SEC Form 4 filed by Director Ambros Reinhard J.
- SEC Form 4 filed by Director Fairey William
- SEC Form 4 filed by Director Von Rickenbach Josef H
- SEC Form 4 filed by Director Musso Alan A
- SEC Form 4 filed by President and CEO Windsor James Brian
- Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Latest VKTX
- Director Kelly-Gemmell Dorothy Elizabeth was granted 6,333 shares (SEC Form 4)
- SEC Form 3 filed by new insider Kelly-Gemmell Dorothy Elizabeth
- SEC Form S-3ASR filed by Viking Therapeutics Inc.
- President & CEO Lian Brian sold $4,947,888 worth of shares (148,517 units at $33.32) and was granted 221,667 shares, increasing direct ownership by 3% to 2,572,441 units (SEC Form 4) to satisfy tax liability
- Chief Financial Officer Zante Greg was granted 31,667 shares and sold $710,141 worth of shares (21,217 units at $33.47), increasing direct ownership by 5% to 212,204 units (SEC Form 4) (for tax liability)
- Chief Operating Officer Mancini Marianna was granted 31,667 shares and sold $609,636 worth of shares (18,217 units at $33.47), increasing direct ownership by 3% to 422,760 units (SEC Form 4) (for withholding tax)
- SEC Form 10-Q filed by Viking Therapeutics Inc.
- Viking Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- SEC Form 144 filed by Viking Therapeutics Inc.